ArticleCell & bioscience2026
CASC19 stabilization by ALYREF via m5C modification and its impact on SCD in colorectal cancer cell aggressiveness and stemness.
Article in Cell & bioscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- ESRG maintains human pluripotent stem cell self-renewal by binding NPM1 to regulate BMP4 protein and TGF-β signaling pathway.Cell & bioscience · 2026Article
- YBX1 as an adaptive RNA hub in cancer: linking state-dependent RNA regulation to tumor immunity, metabolic reprogramming, and therapy resistance.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The progression of colorectal cancer (CRC) is closely associated with aberrant epigenetic regulation. As a key regulator of m5C modification, the role and mechanism of Aly/REF export factor (ALYREF) in CRC remain unclear. This study aims to elucidate the molecular mechanism by which ALYREF regulates the long non-coding RNA cancer susceptibility 19 (CASC19) through m5C modification and its impact on CRC malignancy. In this study, ALYREF was significantly upregulated in CRC tissues and cell lines and was associated with poor patient prognosis. Mechanistically, ALYREF recruited the m5C methyltransferase NOP2/Sun RNA Methyltransferase 2 (NSUN2) to modify the 3'UTR of CASC19, thereby enhancing its stability. CASC19, in turn, recruited Heterogeneous Nuclear Ribonucleoprotein C (HNRNPC) to form a complex that stabilized stearoyl-CoA desaturase (SCD) mRNA, ultimately promoting CRC cell proliferation, metastasis, and stemness. In vivo experiments demonstrated that ALYREF knockdown suppressed tumor growth and lung metastasis, while SCD overexpression reversed the tumor-suppressive effects of CASC19 knockdown. In Conclusion, this study unveils the pivotal regulatory role of the ALYREF/m5C/CASC19/HNRNPC/SCD axis in CRC, providing a novel therapeutic target for disrupting RNA epigenetic-metabolic interactions in cancer treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.